Marksans Pharma

Marksans Pharma Ltd has informed that the Company has received Certificate of suitability for Ciprofloxacin Hydrochloride drug substance from the European Directorate for the Quality of Medicines and Healthcare (EDQM).

This Certificate is recognized by 35 signatory states of the European Pharmacopoeia Convention and by the European Union. Other Countries have also chosen to recognize them. This Certificate of Suitability can be used by the manufacturers of pharmaceutical products in their applications for marketing authorization to demonstrate the compliance of the drug substance used with the official monograph of European Pharmacopoeia.

With the grant of this Certificate of Suitability for Ciprofloxacin Hydrochloride drug
substance by EDQM, the doors of European markets have opened for access for the
Company's API business. The Company is one of the largest manufacturer of Ciprofloxacin in the world.

It is a significant achievement as the Company is focusing on the Regulated Market for its growth. Apart from this, Company has also filed applications for other drug substances which are under consideration with EDQM.